555 related articles for article (PubMed ID: 18035199)
1. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
Crisafulli E; Coletti O; Costi S; Zanasi E; Lorenzi C; Lucic S; Fabbri LM; Bertini M; Clini EM
Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study).
Marchioni CF; Polu JM; Taytard A; Hanard T; Noseda G; Mancini C
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):612-8. PubMed ID: 8688986
[TBL] [Abstract][Full Text] [Related]
3. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
[TBL] [Abstract][Full Text] [Related]
4. Mucolytics for bronchiectasis.
Wilkinson M; Sugumar K; Milan SJ; Hart A; Crockett A; Crossingham I
Cochrane Database Syst Rev; 2014 May; 2014(5):CD001289. PubMed ID: 24789119
[TBL] [Abstract][Full Text] [Related]
5. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
[TBL] [Abstract][Full Text] [Related]
6. [Value of orally administered retard morphine for therapy of severe pulmonary emphysema of the pink-puffer type. A pilot study].
Schönhofer B; Köhler D
Dtsch Med Wochenschr; 1998 Nov; 123(48):1433-8. PubMed ID: 9858950
[TBL] [Abstract][Full Text] [Related]
7. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis.
Martínez-García MA; Perpiñá-Tordera M; Román-Sánchez P; Soler-Cataluña JJ
Respir Med; 2006 Sep; 100(9):1623-32. PubMed ID: 16434174
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of temporary positive expiratory pressure (TPEP) in patients with lung diseases and chronic mucus hypersecretion. The UNIKO® project: a multicentre randomized controlled trial.
Venturelli E; Crisafulli E; DeBiase A; Righi D; Berrighi D; Cavicchioli PP; Vagheggini G; Dabrosca F; Balbi B; Paneroni M; Bianchi L; Vitacca M; Galimberti V; Zaurino M; Schiavoni G; Iattoni A; Ambrosino N; Clini EM
Clin Rehabil; 2013 Apr; 27(4):336-46. PubMed ID: 22967853
[TBL] [Abstract][Full Text] [Related]
9. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of erdosteine, a second generation mucolytic agent, in children with acute rhinosinusitis: a randomized, placebo controlled, double-blinded clinical study.
Unuvar E; Tamay Z; Yildiz I; Toprak S; Kilic A; Aydin S; Kilic G; Guler N; Oguz F; Sidal M
Acta Paediatr; 2010 Apr; 99(4):585-9. PubMed ID: 20055782
[TBL] [Abstract][Full Text] [Related]
12. [The importance of the at risk COPD patients (Stage 0) and clinical differences].
Kömüs N; Tertemiz KC; Sevinç C
Tuberk Toraks; 2008; 56(4):382-9. PubMed ID: 19123073
[TBL] [Abstract][Full Text] [Related]
13. [Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion].
Aubier M; Berdah L
Rev Mal Respir; 1999 Sep; 16(4):521-8. PubMed ID: 10549062
[TBL] [Abstract][Full Text] [Related]
14. Erdosteine for COPD exacerbations.
Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
16. Clinical determinants of the 6-Minute Walk Test in bronchiectasis.
Lee AL; Button BM; Ellis S; Stirling R; Wilson JW; Holland AE; Denehy L
Respir Med; 2009 May; 103(5):780-5. PubMed ID: 19070473
[TBL] [Abstract][Full Text] [Related]
17. Exercise training and inspiratory muscle training in patients with bronchiectasis.
Newall C; Stockley RA; Hill SL
Thorax; 2005 Nov; 60(11):943-8. PubMed ID: 15994254
[TBL] [Abstract][Full Text] [Related]
18. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum.
Daviskas E; Anderson SD; Gomes K; Briffa P; Cochrane B; Chan HK; Young IH; Rubin BK
Respirology; 2005 Jan; 10(1):46-56. PubMed ID: 15691238
[TBL] [Abstract][Full Text] [Related]
19. Self-administered acupressure reduces the symptoms that limit daily activities in bronchiectasis patients: pilot study findings.
Maa SH; Tsou TS; Wang KY; Wang CH; Lin HC; Huang YH
J Clin Nurs; 2007 Apr; 16(4):794-804. PubMed ID: 17402962
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pursed-lips breathing: a breathing pattern retraining strategy for dyspnea reduction.
Nield MA; Soo Hoo GW; Roper JM; Santiago S
J Cardiopulm Rehabil Prev; 2007; 27(4):237-44. PubMed ID: 17667021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
